Acitretin or Tazarotene Gel and Excimer Laser for Treatment of Psoriasis
Status:
Terminated
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind study of excimer (308-nm UVB) laser added to either
tazarotene 0.1% gel or acitretin 25 mg daily for plaque psoriasis.
The primary objective of this study is to compare the improvement of psoriatic plaques with
and without excimer laser (308-nm UVB) treatment, applied in a randomized and blinded
fashion, in subjects on acitretin 25 mg or tazarotene gel 0.1% QD.